Kelly Caitlin S, Wolf Wendy A, Cornelius Emilee M, Peter Megan E, Chapman Katherine S, Dunne Jessica L
T1D Exchange, 101 Federal St Suite 440, Boston, MA, 02110, USA.
Janssen R&D, 1000 U.S. Route 202 South, Raritan, NJ, 08869, USA.
Diabetes Ther. 2024 Oct;15(10):2249-2261. doi: 10.1007/s13300-024-01637-z. Epub 2024 Aug 27.
Screening for islet-specific autoantibodies can identify individuals at risk for type 1 diabetes (T1D). Despite calls for increased nationwide autoantibody screening efforts, it is unclear how many individuals have participated in screening among people who may benefit from it. Moreover, knowledge and perceptions of autoantibody screening in real-world samples are not well understood.
We surveyed a sample of individuals (aged 18+ years old) from T1D Exchange Registry with a personal or family history of T1D to assess their self-reported T1D autoantibody knowledge, experiences, and attitudes. Participants belonged to one of three groups: adults with T1D who had a biological child without T1D or future plans for a child (PWD); parents without T1D who had a biological child with T1D and one or more biological children without T1D (Caregivers); and first-degree adult children or siblings to a person with T1D (Relatives). Descriptive analyses (means, standard deviations, frequencies) are presented by participant groups.
A total of 510 participants enrolled in the study. Across groups, participants reported feeling a little to somewhat knowledgeable about autoantibody screening and positive perceptions of autoantibody screening in general. However, few participants had screened their child without T1D (PWDs, 21.94%; Caregivers, 46.30%) or themselves (Relatives, 19.23%). Among those who had screened, participants reported generally positive experiences. Among those who had not screened, many participants were "undecided" about autoantibody screening (PWD, 38.46%; Caregivers, 40.52%; Relatives, 44.44%). Influences reported for participants' decisions to screen, not screen, or their current indecision differed by group: PWDs (21.70%) and Caregivers (26.87%) most often reported self-initiated research as an influence and Relatives reported they had not previously considered screening (48.28%).
Results highlight the need for more accessible information about screening, including real experiences from those who have screened.
筛查胰岛特异性自身抗体可以识别出1型糖尿病(T1D)的高危个体。尽管呼吁在全国范围内加大自身抗体筛查力度,但尚不清楚在可能从中受益的人群中,有多少人参与了筛查。此外,对于现实样本中自身抗体筛查的知识和认知情况尚不清楚。
我们对来自T1D交换登记处的有T1D个人或家族史的18岁及以上个体样本进行了调查,以评估他们自我报告的T1D自身抗体知识、经历和态度。参与者分为三组之一:患有T1D且有一个未患T1D的亲生孩子或有生育计划的成年人(糖尿病患者);没有T1D但有一个患T1D的亲生孩子和一个或多个未患T1D的亲生孩子的父母(照顾者);以及T1D患者的成年一级亲属或兄弟姐妹(亲属)。描述性分析(均值、标准差、频率)按参与者组呈现。
共有510名参与者登记参加了该研究。在所有组中,参与者表示对自身抗体筛查的了解程度为有点了解到有所了解,总体上对自身抗体筛查持积极看法。然而,很少有参与者对其未患T1D的孩子(糖尿病患者组为21.94%;照顾者组为46.30%)或他们自己(亲属组为19.23%)进行过筛查。在那些进行过筛查的人中,参与者报告的经历总体上是积极的。在那些未进行过筛查的人中,许多参与者对自身抗体筛查“不确定”(糖尿病患者组为38.46%;照顾者组为40.52%;亲属组为44.44%)。报告的影响参与者决定筛查、不筛查或他们当前犹豫不决的因素因组而异:糖尿病患者组(21.70%)和照顾者组(26.87%)最常报告自行开展的研究是一个影响因素,而亲属组报告他们之前没有考虑过筛查(48.28%)。
结果凸显了需要提供更多关于筛查的易获取信息,包括来自已进行筛查者的真实经历。